Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carvana Co (CVNA) vs Novavax Inc (NVAX) Price & Performance

Carvana CoTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Carvana Co vs Novavax Inc — how do they compare? Carvana Co trades at $71.48 (market cap $79.17B), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Carvana Co is far larger — about 60.4× Novavax Inc's market cap. Which is the better fit depends on your goals.

CVNANVAX
Market Cap
$79.17B$1.31B
Sector
Consumer CyclicalHealth
52-Week High
$95.69$11.19
52-Week Low
$56.27$6.22
Enterprise Value
$81.65B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carvana Co

Carvana (CVNA) trades at $70.83, down 4.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported record Q2 2026 results with revenue up 52% year-over-year to $7.38 billion and net income of $513 million, though shares fell due to disappointing full-year EBITDA guidance. Strong cash flow generation continues with 2025 operating cash flow of $1.04 billion.

Outlook remains positive with analyst consensus price target of $87.18 implying 23% upside, but execution risks and premium valuation (P/E 38.1) temper enthusiasm. Key risks include profit margin compression and high debt levels despite improving leverage ratios. The stock faces near-term pressure from guidance concerns but maintains long-term growth potential.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About Carvana Co

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.

Read more on CVNA

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX